Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

Eli Lilly HQ

Lilly closes in on another Cyramza indication

Could be used for colorectal cancer in addition to stomach cancer

EU flag

Lantus faces first biosimilar rival in Europe

Sanofi prepares for insulin challenge from Boehringer and Lilly

- PMLiVE

Lilly says peglispro tops Lantus in diabetes trials

New insulin demonstrates superiority to Sanofi’s product in cutting blood sugar levels

- PMLiVE

Lilly’s psoriasis candidate tops Enbrel in phase III trials

Ixekizumab on course for regulatory filing in first half of 2015

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

Roche - Basel

Mixed findings for Roche in Alzheimer’s study

Crenezumab misses targets but shows some signs of activity

- PMLiVE

Lilly steps up cancer immunotherapy research

Agrees development deal with Immunocore

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links